
Next-generation pipeline for treating mast cell driven diseases
Granular Therapeutics, a UK-based biotech company specialising in precision biologic therapies for treating mast cell driven disorders, announced clinical candidate selection for its lead programme which has demonstrated promising results in initial preclinical studies. Granular Therapeutics has now commenced proof-of-concept (POC) and IND-enabling studies as it prepares… Read More















